Baidu
map

全科医学

订阅

MedSci主页 / 所有栏目 / 全科医学

非劣效、等效性、优效性相关资料汇集

2011-12-10 MedSci原创 MedSci原创

非劣效等效性优效性
关注

非劣性等效性试验的样本含量估计及统计推断.pdf 非劣性等效性试验的样本含量估计及把握度分析.pdf 美国FDA非劣效临床试验指南.pdf EMEA发布的非劣效性界值选择的指导原则.doc  盐酸奥洛他定在中国变应性鼻炎人群的非劣效临床研究设计及其定量分析.pdf 临床新药试验中非劣效性检验界值的确定方法.pdf 随机模拟法验证非劣效临床试验样本量计算公式.pdf

非劣性等效性试验的样本含量估计及统计推断.pdf 非劣性等效性试验的样本含量估计及把握度分析.pdf 美国FDA非劣效临床试验指南.pdf EMEA发布的非劣效性界值选择的指导原则.doc  盐酸奥洛他定在中国变应性鼻炎人群的非劣效临床研究设计及其定量分析.pdf 临床新药试验中非劣效性检验界值的确定方法.pdf 随机模拟法验证非劣效临床试验样本量计算公式.pdf 美国FDA对抗菌药物临床试验非劣效设计的考虑.pdf 临床试验中采用非劣效设计应该关注的问题.pdf 临床试验中采用非劣效设计应该关注的问题.pdf 非劣效、等效性、优效性.doc 安慰剂和阳性药对照的三臂非劣效临床试验的样本含量估计和统计推断.pdf 配对二项数据等效性_非劣效性评价的样本含量估计和假设检验.pdf 新药临床非劣性及等效性试验中的例数估计和等效标准.pdf 第八讲_非劣效性和等效性随机对照试验的报告规范——CONSORT声明的扩展.pdf 非劣效、等效性、优效性.doc  

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2112309, encodeId=a89621123093b, content=看不到, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=24a42159834, createdName=1202cbb3m56暂无昵称, createdTime=Tue Jan 31 02:22:36 CST 2023, time=2023-01-31, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=4769, encodeId=c61d4e6929, content=很有用。多谢！, beContent=null, objectType=article, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200530/ab625e79df6149cd87fc470de0168d84/c03870e1346341d7947080ec376753e8.jpg, createdBy=135c13336, createdName=maoqianguo, createdTime=Sun Sep 23 21:52:00 CST 2012, time=2012-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907920, encodeId=a05b190e92000, content=<a href='/topic/show?id=b3c199328f2' target=_blank style='color:#2F92EE;'>#非劣效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99328, encryptionId=b3c199328f2, topicName=非劣效)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Mon Nov 12 04:23:00 CST 2012, time=2012-11-12, status=1, ipAttribution=)]
    2023-01-31 1202cbb3m56暂无昵称 来自广东省

    看不到

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2112309, encodeId=a89621123093b, content=看不到, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=24a42159834, createdName=1202cbb3m56暂无昵称, createdTime=Tue Jan 31 02:22:36 CST 2023, time=2023-01-31, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=4769, encodeId=c61d4e6929, content=很有用。多谢！, beContent=null, objectType=article, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200530/ab625e79df6149cd87fc470de0168d84/c03870e1346341d7947080ec376753e8.jpg, createdBy=135c13336, createdName=maoqianguo, createdTime=Sun Sep 23 21:52:00 CST 2012, time=2012-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907920, encodeId=a05b190e92000, content=<a href='/topic/show?id=b3c199328f2' target=_blank style='color:#2F92EE;'>#非劣效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99328, encryptionId=b3c199328f2, topicName=非劣效)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Mon Nov 12 04:23:00 CST 2012, time=2012-11-12, status=1, ipAttribution=)]
    2012-09-23 maoqianguo

    很有用。多谢！

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2112309, encodeId=a89621123093b, content=看不到, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=24a42159834, createdName=1202cbb3m56暂无昵称, createdTime=Tue Jan 31 02:22:36 CST 2023, time=2023-01-31, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=4769, encodeId=c61d4e6929, content=很有用。多谢！, beContent=null, objectType=article, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200530/ab625e79df6149cd87fc470de0168d84/c03870e1346341d7947080ec376753e8.jpg, createdBy=135c13336, createdName=maoqianguo, createdTime=Sun Sep 23 21:52:00 CST 2012, time=2012-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907920, encodeId=a05b190e92000, content=<a href='/topic/show?id=b3c199328f2' target=_blank style='color:#2F92EE;'>#非劣效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99328, encryptionId=b3c199328f2, topicName=非劣效)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Mon Nov 12 04:23:00 CST 2012, time=2012-11-12, status=1, ipAttribution=)]
    2012-11-12 tonychen21

    #非劣效#

    0

Baidu
map
Baidu
map
Baidu
map